DrugPatentWatch Database Preview
Investigational Drug Information for LY03005
Email this page to a colleague
What is the drug development status for LY03005?
LY03005 is an investigational drug.
There have been 8 clinical trials for LY03005.
The most recent clinical trial was a Phase 3 trial, which was initiated on December 5th 2018.
The most common disease conditions in clinical trials are Depressive Disorder, Major, Depressive Disorder, and Depression. The leading clinical trial sponsors are Luye Pharma Group Ltd., Shandong Luye Pharmaceutical Co., Ltd., and [disabled in preview].
There are four US patents protecting this investigational drug and fifty-one international patents.
Summary for LY03005
| US Patents | 4 |
| International Patents | 51 |
| US Patent Applications | 8 |
| WIPO Patent Applications | 2 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 3 (2018-12-05) |
| Vendors | 3 |
Recent Clinical Trials for LY03005
| Title | Sponsor | Phase |
|---|---|---|
| A Relative Bioavailability Food Effect Study of LY03005 | Luye Pharma Group Ltd. | Phase 1 |
| A Study to Evaluate the Efficacy and Safety of Ansofaxine Hydrochloride Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD) | Luye Pharma Group Ltd. | Phase 3 |
| A Study of LY03005 vs Pristiq | Luye Pharma Group Ltd. | Phase 1 |
Clinical Trial Summary for LY03005
Top disease conditions for LY03005
Top clinical trial sponsors for LY03005
US Patents for LY03005
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| LY03005 | ⤷ Sign up for a Free Trial | Compounds for inhibition of 5-hydroxytryptamine and norepinephrine reuptake or for treatment of depression disorders, their preparation processes and uses thereof | Shandong Luye Pharmaceutical Co., Ltd. (Yantai, Shandong, CN) Li; Youxin (Zhuzhou, Hunan, CN) | ⤷ Sign up for a Free Trial |
| LY03005 | ⤷ Sign up for a Free Trial | Compounds for inhibition of 5-hydroxytryptamine and norepinephrine reuptake or for treatment of depression disorders, their preparation processes and uses thereof | Shandong Luye Pharmaceutical Co. Ltd. (Yantai, CN) Li; Youxin (Zhuzhou, CN) | ⤷ Sign up for a Free Trial |
| LY03005 | ⤷ Sign up for a Free Trial | Polymorphs of 4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenyl 4-methyl-benzoate hydrochloride, methods for preparing the same and use of the same | Shangong Luye Pharmaceutical Co., Ltd. (Yantai, Shandong, CN) Li; Youxin (Langenfeld, DE) | ⤷ Sign up for a Free Trial |
| LY03005 | ⤷ Sign up for a Free Trial | Polymorphs of 4-[2-dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenyl 4-methylbenzoate hydrochloride, methods of preparing the same and use of the same | SHANDONG LUYE PHARMACEUTICAL CO., LTD. (Yantai, CN) Li; Youxin (Langenfield, DE) | ⤷ Sign up for a Free Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for LY03005
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| LY03005 | Australia | AU2006257558 | 2025-06-17 | ⤷ Sign up for a Free Trial |
| LY03005 | Canada | CA2612413 | 2025-06-17 | ⤷ Sign up for a Free Trial |
| LY03005 | China | CN1955159 | 2025-06-17 | ⤷ Sign up for a Free Trial |
| LY03005 | Denmark | DK1897867 | 2025-06-17 | ⤷ Sign up for a Free Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
